{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:58:47Z","timestamp":1761418727696},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/wad.0b013e318214b7d0","type":"journal-article","created":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T05:55:45Z","timestamp":1301378145000},"page":"1-7","source":"Crossref","is-referenced-by-count":10,"title":["Psychotropic Drug Effects on Gene Transcriptomics Relevant to Alzheimer Disease"],"prefix":"10.1097","volume":"26","author":[{"given":"Edward C.","family":"Lauterbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210128","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/jnp.2010.22.2.130","article-title":"Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications.","volume":"22","author":"Lauterbach","year":"2010","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R3-1-20210128","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.npp.1301497","article-title":"Genetic regulation of behavioral and neuronal responses to fluoxetine.","volume":"33","author":"Miller","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R4-1-20210128","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/sj.npp.1301002","article-title":"Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique.","volume":"31","author":"Fatemi","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R5-1-20210128","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","article-title":"Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimers disease.","volume":"41","author":"Harold","year":"2009","journal-title":"Nat Genet"},{"key":"R6-1-20210128","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","article-title":"Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimers disease.","volume":"41","author":"Lambert","year":"2009","journal-title":"Nat Genet"},{"key":"R7-1-20210128","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1001\/jama.2010.574","article-title":"CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease.","volume":"303","author":"Seshadri","year":"2010","journal-title":"JAMA"},{"key":"R8-1-20210128","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.brainresrev.2009.05.007","article-title":"Clusterin: a forgotten player in Alzheimers disease.","volume":"61","author":"Nuutinen","year":"2009","journal-title":"Brain Res Rev"},{"key":"R9-1-20210128","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/humu.20953","article-title":"Genomic convergence to identify candidate genes for Alzheimer disease on chromosome 10.","volume":"30","author":"Liang","year":"2009","journal-title":"Hum Mutat"},{"key":"R10-1-20210128","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.brainres.2008.10.019","article-title":"Expression and genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A polymorphism in sporadic Alzheimers disease in a Southern China population.","volume":"1247","author":"Yang","year":"2009","journal-title":"Brain Res"},{"key":"R11-1-20210128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0304-3940(91)90490-K","article-title":"Elevated circulating tumor necrosis factor levels in Alzheimers disease.","volume":"129","author":"Fillit","year":"1991","journal-title":"Neurosci Lett"},{"key":"R12-1-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1020568013953","article-title":"Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia.","volume":"19","author":"Tarkowski","year":"1999","journal-title":"J Clin Immunol"},{"key":"R13-1-20210128","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1749-6632.2000.tb05399.x","article-title":"Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimers disease.","volume":"917","author":"Solerte","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R14-1-20210128","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1017\/S1461145709990101","article-title":"Reduced TNF-alpha and increased IGF-I levels in the serum of Alzheimers disease patients treated with the neurotrophic agent Cerebrolysin.","volume":"12","author":"Anton Alvarez","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"R15-1-20210128","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3233\/JAD-2010-1253","article-title":"Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimers disease and non-demented patients.","volume":"19","author":"Cheng","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"R16-1-20210128","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nbd.2009.01.006","article-title":"Inhibition of soluble TNF signaling in a mouse model of Alzheimers disease prevents pre-plaque amyloid-associated neuropathology.","volume":"34","author":"McAlpine","year":"2009","journal-title":"Neurobiol Dis"},{"key":"R17-1-20210128","first-page":"25","article-title":"TNF-alpha modulation for treatment of Alzheimers disease: a 6-month pilot study.","volume":"8","author":"Tobinick","year":"2006","journal-title":"Med Gen Med"},{"key":"R18-1-20210128","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/archpsyc.65.4.395","article-title":"A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes.","volume":"65","author":"Padmos","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"R19-1-20210128","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nm1555","article-title":"Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease.","volume":"13","author":"El Khoury","year":"2007","journal-title":"Nat Med"},{"key":"R20-1-20210128","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s004390050533","article-title":"Human transferrin (Tf): a single mutation at codon 570 determines Tf C1 or Tf C2 variant.","volume":"100","author":"Namekata","year":"1997","journal-title":"Hum Genet"},{"key":"R21-1-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmg.2003.015552","article-title":"Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimers disease.","volume":"41","author":"Robson","year":"2004","journal-title":"J Med Genet"},{"key":"R22-1-20210128","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-244X-7-46","article-title":"Inflammation-related genes up-regulated in schizophrenia brains.","volume":"7","author":"Saetre","year":"2007","journal-title":"BMC Psychiatry"},{"key":"R23-1-20210128","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/hmg\/ddm348","article-title":"Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimers and Parkinsons disease.","volume":"17","author":"Li","year":"2008","journal-title":"Hum Mol Genet"},{"key":"R24-1-20210128","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ajmg.b.30889","article-title":"An association study between granulin gene polymorphisms and Alzheimers disease in Finnish population.","volume":"150B","author":"Viswanathan","year":"2009","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R25-1-20210128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3233\/JAD-2009-1170","article-title":"Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimers disease.","volume":"18","author":"Fenoglio","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"R26-1-20210128","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1001\/archneur.64.10.1436","article-title":"Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family.","volume":"64","author":"Brouwers","year":"2007","journal-title":"Arch Neurol"},{"key":"R27-1-20210128","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nature05017","article-title":"Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21.","volume":"442","author":"Cruts","year":"2006","journal-title":"Nature"},{"key":"R28-1-20210128","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/sj.mp.4001198","article-title":"Tau negative frontal lobe dementia at 17q21: significant finemapping of the candidate region to a 4.8 cM interval.","volume":"7","author":"Rademakers","year":"2002","journal-title":"Mol Psychiatry"},{"key":"R29-1-20210128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jns.2009.07.011","article-title":"Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimers disease.","volume":"287","author":"Carecchio","year":"2009","journal-title":"J Neurol Sci"},{"key":"R30-1-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/archneurol.2010.113","article-title":"Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin.","volume":"67","author":"Kelley","year":"2010","journal-title":"Arch Neurol"},{"key":"R31-1-20210128","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.neurobiolaging.2003.11.002","article-title":"A polymorphism of the interleukin-1 beta gene at position 3953 influences progression and neuro-pathological hallmarks of Alzheimers disease.","volume":"25","author":"Licastro","year":"2004","journal-title":"Neurobiol Aging"},{"key":"R32-1-20210128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.20120","article-title":"The interleukin 1beta gene promoter polymorphism (-511) acts as a risk factor for psychosis in Alzheimers dementia.","volume":"56","author":"Craig","year":"2004","journal-title":"Ann Neurol"},{"key":"R33-1-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajmg.b.20086","article-title":"Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimers disease.","volume":"124B","author":"McCulley","year":"2004","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"R34-1-20210128","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0306-4522(98)00680-0","article-title":"Interleukin-1beta activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimers disease.","volume":"91","author":"Casamenti","year":"1999","journal-title":"Neuroscience"},{"key":"R35-1-20210128","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/jnnp.74.6.788","article-title":"Systemic infection, interleukin 1beta, and cognitive decline in Alzheimers disease.","volume":"74","author":"Holmes","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R36-1-20210128","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0306-4522(94)90398-0","article-title":"Induction of immune system mediators in the hippocampal formation in Alzheimers and Parkinsons diseases: selective effects on specific interleukins and interleukin receptors.","volume":"61","author":"Araujo","year":"1994","journal-title":"Neuroscience"},{"key":"R37-1-20210128","first-page":"141","article-title":"Brain interleukin-1 beta in Alzheimers disease and vascular dementia.","volume":"16","author":"Cacabelos","year":"1994","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"R38-1-20210128","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.biopsych.2008.10.018","article-title":"The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia.","volume":"65","author":"Song","year":"2009","journal-title":"Biol Psychiatry"},{"key":"R39-1-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0304-3940(96)12985-2","article-title":"Induction of interleukin-1 beta and interleukin-1 receptor antagonist mRNA by chronic treatment with various psychotropics in widespread area of rat brain.","volume":"215","author":"Suzuki","year":"1996","journal-title":"Neurosci Lett"},{"key":"R40-1-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0197-4580(92)90043-W","article-title":"Reduction of thyroid hormone receptor c-ERB A alpha mRNA levels in the hippocampus of Alzheimer as compared to Huntington brain.","volume":"13","author":"Sutherland","year":"1992","journal-title":"Neurobiol Aging"},{"key":"R41-1-20210128","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1111\/j.1742-4658.2009.07094.x","article-title":"Overexpression of Tfam protects mitochondria against beta-amyloid-induced oxidative damage in SH-SY5Y cells.","volume":"276","author":"Xu","year":"2009","journal-title":"FEBS J"},{"key":"R42-1-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3233\/JAD-2008-13305","article-title":"Mitochondrial transcription factor A (TFAM) gene variation and risk of late-onset Alzheimers disease.","volume":"13","author":"Alvarez","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"R43-1-20210128","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.55.4.480","article-title":"Association of an interleukin 1 alpha polymorphism with Alzheimers disease.","volume":"55","author":"Du","year":"2000","journal-title":"Neurology"},{"key":"R44-1-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N","article-title":"Association of early-onset Alzheimers disease with an interleukin-1alpha gene polymorphism.","volume":"47","author":"Grimaldi","year":"2000","journal-title":"Ann Neurol"},{"key":"R45-1-20210128","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/1531-8249(200003)47:3<365::AID-ANA13>3.0.CO;2-G","article-title":"Association of interleukin-1 gene polymorphisms with Alzheimers disease.","volume":"47","author":"Nicoll","year":"2000","journal-title":"Ann Neurol"},{"key":"R46-1-20210128","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1212\/WNL.56.11.1595","article-title":"Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha -889 1 allele.","volume":"56","author":"Murphy","year":"2001","journal-title":"Neurology"},{"key":"R47-1-20210128","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ana.1068","article-title":"Gene polymorphisms of interleukin-1alpha influence the course of Alzheimers disease.","volume":"49","author":"Kolsch","year":"2001","journal-title":"Ann Neurol"},{"key":"R48-1-20210128","doi-asserted-by":"crossref","first-page":"8215","DOI":"10.1073\/pnas.0509725103","article-title":"PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice.","volume":"103","author":"Choi","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R49-1-20210128","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1126\/science.289.5486.1925","article-title":"Signal transduction through prion protein.","volume":"289","author":"Mouillet-Richard","year":"2000","journal-title":"Science"},{"key":"R50-1-20210128","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1073\/pnas.0511290103","article-title":"Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis.","volume":"103","author":"Steele","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R51-1-20210128","doi-asserted-by":"crossref","first-page":"39145","DOI":"10.1074\/jbc.C100443200","article-title":"Prion protein protects human neurons against Bax-mediated apoptosis.","volume":"276","author":"Bounhar","year":"2001","journal-title":"J Biol Chem"},{"key":"R52-1-20210128","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nature07761","article-title":"Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.","volume":"457","author":"Lauren","year":"2009","journal-title":"Nature"},{"key":"R53-1-20210128","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1212\/WNL.51.3.734","article-title":"Polymorphism of the prion protein is associated with cognitive impairment in the elderly: the EVA study.","volume":"51","author":"Berr","year":"1998","journal-title":"Neurology"},{"key":"R54-1-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ana.10658","article-title":"Early cognitive decline is associated with prion protein codon 129 polymorphism.","volume":"54","author":"Croes","year":"2003","journal-title":"Ann Neurol"},{"key":"R55-1-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ana.10507","article-title":"PRNP Val129 homozygosity increases risk for early-onset Alzheimers disease.","volume":"53","author":"Dermaut","year":"2003","journal-title":"Ann Neurol"},{"key":"R56-1-20210128","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/01.WNL.0000130198.72589.69","article-title":"Prion protein codon 129 polymorphism and risk of Alzheimer disease.","volume":"63","author":"Riemenschneider","year":"2004","journal-title":"Neurology"},{"key":"R57-1-20210128","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nature09325","article-title":"Gamma-secretase activating protein is a therapeutic target for Alzheimers disease.","volume":"467","author":"He","year":"2010","journal-title":"Nature"},{"key":"R58-1-20210128","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/gm34","article-title":"Genetics of Alzheimers disease: recent advances.","volume":"1","author":"Avramopoulos","year":"2009","journal-title":"Genome Med"},{"key":"R59-1-20210128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1586\/erm.10.48","article-title":"Advances and perspectives from genetic research: development of biological markers in Alzheimers disease.","volume":"10","author":"Zetzsche","year":"2010","journal-title":"Expert Rev Mol Diagn"},{"key":"R60-1-20210128","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archneurol.2010.97","article-title":"Identification of Alzheimer risk factors through whole-genome analysis.","volume":"67","author":"Hardy","year":"2010","journal-title":"Arch Neurol"},{"key":"R61-1-20210128","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1093\/hmg\/ddq221","article-title":"Association of CR1, CLU and PICALM with Alzheimers disease in a cohort of clinically characterized and neuropathologically verified individuals.","volume":"19","author":"Corneveaux","year":"2010","journal-title":"Hum Mol Genet"},{"key":"R62-1-20210128","doi-asserted-by":"crossref","first-page":"e13950","DOI":"10.1371\/journal.pone.0013950","article-title":"Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimers disease.","volume":"5","author":"Jones","year":"2010","journal-title":"PLoS One"},{"key":"R63-1-20210128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2210-9-10","article-title":"Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells.","volume":"9","author":"Vik-Mo","year":"2009","journal-title":"BMC Pharmacol"},{"key":"R64-1-20210128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neulet.2010.03.041","article-title":"Valproic acid stimulates clusterin expression in human astrocytes: implications for Alzheimers disease.","volume":"475","author":"Nuutinen","year":"2010","journal-title":"Neurosci Lett"},{"key":"R65-1-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1460-9568.2009.06787.x","article-title":"Epigenetic dysregulation in cognitive disorders.","volume":"30","author":"Graff","year":"2009","journal-title":"Eur J Neurosci"},{"issue":"suppl 1","key":"R66-1-20210128","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/(SICI)1099-1166(200004)15:1+<S2::AID-GPS159>3.0.CO;2-3","article-title":"Introduction to behavioural and psychological symptoms of dementia (BPSD).","volume":"15","author":"Finkel","year":"2000","journal-title":"Int J Geriatr Psychiatry"},{"key":"R67-1-20210128","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/01.WNL.0000150886.50187.30","article-title":"Atherosclerosis and AD: analysis of data from the US National Alzheimers coordinating center.","volume":"64","author":"Honig","year":"2005","journal-title":"Neurology"},{"key":"R68-1-20210128","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1176\/ajp.147.8.1049","article-title":"Psychiatric symptoms and nursing home placement of patients with Alzheimers disease.","volume":"147","author":"Steele","year":"1990","journal-title":"Am J Psychiatry"},{"key":"R69-1-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000160958","article-title":"Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimers disease.","volume":"26","author":"Pritchard","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R70-1-20210128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.neurobiolaging.2006.10.011","article-title":"Role of 5HT 2A and 5HT 2C polymorphisms in behavioural and psychological symptoms of Alzheimers disease.","volume":"29","author":"Pritchard","year":"2008","journal-title":"Neurobiol Aging"},{"key":"R71-1-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000107081","article-title":"Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients.","volume":"24","author":"Pritchard","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R72-1-20210128","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4088\/JCP.v69n0602","article-title":"Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy.","volume":"69","author":"Salzman","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R73-1-20210128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1176\/jnp.2010.22.1.8","article-title":"Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.","volume":"22","author":"Lauterbach","year":"2010","journal-title":"J Neuropsychiatry Clin Neurosci"}],"container-title":["Alzheimer Disease &amp; Associated Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002093-201201000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:50:19Z","timestamp":1618278619000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002093-201201000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wad.0b013e318214b7d0","relation":{},"ISSN":["0893-0341"],"issn-type":[{"value":"0893-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}